Sero-diagnosis of *Chlamydia trachomatis* and Molecular Detection of Genital Oncogenic *Human Papilloma Virus* Among Cameroonian Women

Bernard Wabo¹, Dickson Shey Nsagha²,*, Théophile Njamen Nana³, Clement Jules Nguedia Assob¹

¹Department of Medical Laboratory Science, Faculty of Health Sciences, University of Buea, Buea, Cameroon
²Department of Public Health and Hygiene, Faculty of Health Sciences, University of Buea, Buea, Cameroon
³Department of Obstetrics and Gynaecology, Faculty of Health Sciences, University of Buea, Buea, Cameroon

Email address: wabobernard52@gmail.com (B. Wabo), nsaghads@hotmail.com (D.S. Nsagha), njanatheo@yahoo.fr (T.N. Nana), juleclement@yahoo.fr (C. J. N. Assob)

*Corresponding author

To cite this article: Bernard Wabo, Dickson Shey Nsagha, Théophile Njamen Nana, Clement Jules Nguedia Assob. Sero-diagnosis of *Chlamydia trachomatis* and Molecular Detection of Genital Oncogenic *Human Papilloma Virus* Among Cameroonian Women. European Journal of Clinical and Biomedical Sciences. Vol. 6, No. 5, 2020, pp. 90-99. doi: 10.11648/j.ejcbs.20200605.14

Abstract: Cervical cancer is a preventable public health concern ranking second among women’s cancer in Cameroon. *Human papilloma virus* (HPV) is the main causative agent with *Chlamydia trachomatis* being suggested as the co-factor. Our objective was to characterize high risk (hr) HPV types and to detect *Chlamydia trachomatis* antibodies among Cameroonian women with and without cervical cancer. Methods: This unmatched case-control study enrolled 100 cases with cervical cancer and 200 controls with normal cytology aged 25-65 years in four reference hospitals in Douala and Yaoundé (Cameroon). Consented participants filled a structured questionnaire and data on socio-demographic characteristics collected. *Chlamydia trachomatis* antibodies were detected by the Enzyme Linked Immuno-Sorbent Assay technique (ELISA) and hr HPV-DNA by PCR technique. Descriptive statistics was conducted to provide frequencies and percentages and the logistic regression analysis to assess the association between categorical data. p < 0.05 was considered significant. Results: Our data showed 39 (39.0%) cases aged 39-52 years compared to 96 (48.0%) controls aged 25-38 years (p=0.001). We found 82 (82.0%) cases compared to 131 (65.5%) controls with hr HPV infections. HPV 16 was most prevalent being found in 29 (29.0%) cases compared to 69 (34.5%) controls. *Chlamydia trachomatis* IgG / hr HPV co-infections were detected in 20 (20.0%) cases compared to 33 (16.5%) controls but with no significant association with cervical cancer (aOR=1.87; 95%CI: 0.58-5.97; p=0.293). *Chlamydia trachomatis* IgM (aOR=3.50; 95%CI: 1.16-10.49; p=0.025) was significantly associated with cervical cancer. Conclusion: Hr HPV- DNA was high in cases than in controls. *Chlamydia trachomatis* single infection and *Chlamydia trachomatis*/hr HPV co-infections were not significantly associated to precancerous lesions thus, necessitating further investigations.

Keywords: Precancerous Lesions, *Human papilloma virus*, *Chlamydia trachomatis*, Co-infection, Case-control Study

1. Introduction

The *Human papilloma virus* (HPV) family comprises more than 200 different types [1]. Almost all cervical cancers are caused by persistent infection with certain types of HPV [2]. Infections caused by high risk (hr) HPV are responsible for 7.7% cases of cervical cancer mainly in developing countries [3, 4]. Most HPV infections are transient and only a small minority of women with long term, persistent infections are at an increased risk of progression to precancerous cervical lesions and cervical cancer [5]. A number of factors have been found to contribute to cervical cancer including: high parity, tobacco smoking, long-term hormonal contraceptive use, co-infection with *C. trachomatis*, *Herpes simplex virus* type 2, HIV, immunosuppression, certain dietary deficiencies, cancer,
imbalanced vaginal flora, having an uncircumcised male partner and low socio-economic status [1, 6]. The role of sexually transmitted infections (STIs) other than HPV as cofactors in cervical carcinogenesis due to HPV is a matter of debate. Most STIs are suggested to be associated with an inflammatory response/process which facilitate HPV entry into target cells, as well as with the persistence of infection [7].

C. trachomatis is an intracellular bacterium with spherical to ovoid obligate shape that is found worldwide [8]. There are 17 different serotypes of C. trachomatis: E, F, G, D, K, J, H, B, Ia with the serovars D-K causing the urogenital tract infection [9]. Most C. trachomatis infections in women may result in pelvic inflammatory diseases, preterm delivery, and premature rupture of membranes, low birth weight and still birth. There are also an increased risk of post abortion, post caesarean section and post-partum maternal infections [10].

HPV and C. trachomatis are the cause of most common STIs worldwide; they share similar behavioural risk factors, such as younger age and higher numbers of sexual partners [11]. As a result, the two infections could occur concurrently [11, 12]. This association has also been suspected in the aetiology of cervical cancer independently of HPV status [13]. Given that the endocervix is the major site of C. trachomatis infection in the lower genital tract, it is hypothesized that C. trachomatis infection may play a role in the initiation of malignant transformation of the glandular endocervical epithelium via the mechanisms related to HPV co-infection. In addition, C. trachomatis may play a role in the progression of adenocarcinoma by evoking the inflammatory response that damages the mucosal barrier including the basement membrane [11, 12, 14].

Issues related to HPV/ C. trachomatis single or co-infections remain a matter of debates. In Cameroon, there is paucity in the epidemiological data on HPV/ C. trachomatis co-infections and their role in the aetiology of cervical cancer. The objective of this study was to detect genital HPV- DNA types and C. trachomatis antibodies in women with and without cervical precancerous lesions in two main cities of Cameroon.

2. Methods

2.1. Study Design

This unmatched case-control study enrolled women screened for cervical cancer between June to November 2018 at the Gynaecology units of four reference hospitals in Douala [the Douala General Hospital (DGH) and the Douala Gynaeco-Obstetric and Paediatric Hospital (DGOPH)] and in Yaoundé [the Yaoundé University Teaching Hospital (YUTH) and the Yaoundé Gynaeco-Obstetrics and Paediatrics Hospital (YGOPH)] respectively the economic and political capitals of Cameroon.

Inclusion criteria for cases: Cases were 100 cervical cancer patients randomly selected among those diagnosed with abnormal cytology as atypical squamous cells of undetermined significance (ASCUS), low grade squamous intraepithelial lesions (LSIL), high low grade squamous intraepithelial lesions (HISIL). Only cases who participated in the free cervical cancer screening campaign organized for the purpose of this study were included.

Exclusion criteria for cases: Those cases who had initiated cervical cancer therapy and those with prolong cervico-vaginal bleeding were excluded from the study.

Inclusion criteria for controls: We included 200 non-cervical cancer patients randomly selected among those diagnosed with normal cytology by the Pap test. Only controls who participated in the free cervical cancer screening campaign organized for the purpose of this study were included.

Exclusion criteria for controls: We excluded controls with the following characteristics: HPV vaccination, pregnancy, radical hysterectomy, virgins and those with prolong cervico-vaginal bleeding.

2.2. Sample size Calculation

The sample size for a case - controls was obtained using the Kelsey method [15]. Where: N=sample size for cases=100, 80% the power, Zα=0.84, at a 0.05 significance level Zβ=1.96, OR=odds ratio of 2.0. The proportion exposed in the control group was 36.3% [16] (Pcontrol exp), P1=proportion of exposed in the control group, P2=proportion of exposed in the case group. Using the ratio (r) of one case to two controls, we included 100 cases and 200 controls in the study.

2.3. Sampling Technique

Sampling method for cases: A systematic random sampling technique using the calculated skip interval of 1.13 (skip intervals=K=Total population/sample size) was conducted to select 100 cases for this study: thus starting from the first case, any other case was chosen at an interval of two until we got 100 cases.

Sampling method for controls: A systematic random sampling technique using the calculated skip interval of 4.06 (skip intervals=K=Total population/sample size) was conducted to select 200 controls for this study: thus starting from the first case, any other case was chosen at an interval of five until we got 200 controls.

2.4. Ethical Clearance

The study was approved by the Faculty of Health Science Institutional Review Board of the University of Buea, Cameroon (N°: 2018/0254/UB/SG/IRB/FHS). The aim of the study, benefits and potential risk were clearly explained to each participant. Verbal and written informed consent to attest adherence in the study was provided by each of them. Anonymity and confidentially were respected.

2.5. Sample Collection

2.5.1. Administration of Questionnaire

The ward of the gynaecology or family planning unit of each selected health facility was used to recruit participants.
who filled a structured questionnaire consisting of questions on socio-demographic and reproductive histories. Following verification of the questionnaire for its completeness, an identification code was attributed to each of them. They were later conveyed for the blood and the endocervical sample collection in a private gynaecology consultation room following an attributed identification code.

2.5.2. Collection and Handling of Venous Blood Samples

Each participant was comfortably seated and reassured of the little pain they might feel when the sterile needle will be introduced into the cubital vein. After sterilisation with 70% alcohol, 4 millilitres (ml) of venous blood sample was aseptically obtained by venepuncture using sterile vacutainer needle and gently introduced into a plain dried 5 ml vacutainer tube. The blood was then allowed to clot. At the end of the day, all blood samples were centrifuged at 12 000 g for 10 minutes and 500 µl of serum extracted avoiding mixing with blood cells and aliquoted into a 1.5 ml eppendorf tube clearly labelled with the participants’ identification number. The serum sample obtained was stored at -20°C freezer until analysis [17]. Blood samples from different study sites were transported in the cool environment (+4°- 8°C) to the Applied Biochemistry Laboratory of the Faculty of Health Sciences- University of Buea for analysis.

2.5.3. Collection and Handling of Cervical Smear

Following physical examination by a gynaecologist, a sterile disposable speculum was aseptically inserted into the illuminated vagina to observe the external os [18]. A sterile cytobrush was then aseptically inserted into the endocervical canal (about 1.0-1.5 centimeters) until the largest bristles touched the ectocervix through a disposable speculum. The brush was rotated in an anti-clockwise direction (180°C) and slowly removed from the cervical canal avoiding vaginal secretions and mucus. The secretions of the endocervix obtained with the cytobrush were suspended in 500 µl of Sacace transport medium plus solution (Sacace Biotechnologies Srl, Italy) contained in a 2.0 ml disposable Vacutainer needle and gently introduced into a plain dried 5 ml vacutainer tube. The blood was then allowed to clot. At the end of the day, all blood samples were centrifuged at 12 000 g for 10 minutes and 500 µl of serum extracted avoiding mixing with blood cells and aliquoted into a 1.5 ml eppendorf tube clearly labelled with the participants’ identification number. The serum sample obtained was stored at -20°C freezer until analysis [17]. Blood samples from different study sites were transported in the cool environment (+4°- 8°C) to the Applied Biochemistry Laboratory of the Faculty of Health Sciences- University of Buea for analysis.

2.5.4. Laboratory Procedures

i) Venous Blood Sample Analysis

Data on C. trachomatis (IgG, IgM, IgA) antibodies were indirectly obtained in the serum by Enzyme linked immunosorbent assay (ELISA) technique using Vircell diagnostic kits according to the manufacturer’s instructions (Virecell Microbiologists, Spain). The validity of ELISA test results was considered at Optical Density > 0.9 for positive control, < 0.5 for negative control and > 0.5 and < 1.5 for the cut-off control. A participant was classified as negative if the antibody index was ≤ 9 and positive if > 9 according to the formula: Antibody index=(sample OD/cut-off OD) X 10.

ii) Detection of High Risk Human Papilloma Virus by Polymerase Chain Reaction

The PCR technique was used to detect 12 hr HPV- DNA in the endocervical secretions with strict adherence to the manufacturer’s instruction. The procedure involved:

An extraction of the HPV- DNA in the endocervical samples and controls using DNA-Sorb-A extraction kit according to the manufacturer’s instructions (Sacace Biotechnologies Srl, Italy). The purity of the extracted DNA samples was confirmed using Nanodrop® 2000 spectrophotometer (Fisher thermoscientific, USA).

Multiplex amplification of the isolated DNA was conducted on Biorad T100 thermocycler (Biorad) using HPV 12 high risk typing kit (Sacace Biotechnologies Srl, Italy). Each PCR-mix-1 tube contained primers directed against regions of four HPV types and β-globine gene used as Internal Control and the TaqFpol enzyme. The amplification procedure had three cycles with different reaction temperatures: 1 cycle of 15 minutes at 95°C, 42 cycles (30 seconds at 95°C, 40 seconds at 63°C, and 50 seconds at 72°C), and 1 cycle of 1 minute at 72°C. Storage was done at 10°C for 1 minute.

The amplified products were detected by gel electrophoresis and the bands revealed using a white 12 UV transilluminator (Gel logistic 112 manufactured by Kodak). The length of the amplified samples was determined using a 100 bp ladder.

2.6. Statistical Analysis

Statistical analysis was conducted using the Statistical Package for Social Sciences (SPSS) v 20 and the results presented on tables. Continuous variables were computed as mean and standard deviation (SD) and categorical variables as frequencies and percentages. The association between categorical data and the infections was obtained using the Chi square (X²) and the logistic regression analysis (odd ratio at 95% confidence interval). The level of significance was considered at p< 0.05.

3. Results

3.1. Socio-demographic, Behavioural and Reproductive Characteristics of Cases and Controls

Table 1 presents 29 (29.0%) cases and 96 (48.0%) controls aged 25-38 years. Their mean ages were 44.7 +/-11.1 SD years for the cases and 39.3 +/-9.7 SD years for the controls. Of the 180 married participants, 61 (61.0%) were cases and 119 (59.5%) were controls. Likewise, 34 (34.0%) cases had secondary school education respectively.

Of the 200 participants who had never used condom, 64 (64.0%) were cases compared to 136 (68.0%) controls. On the other hand, 28 (28.0%) cases compared to 50 (25.0%)
controls used oral contraceptive occasionally. We also found that 44 (44.0%) cases compared 82 (41.0%) controls with more than five parities (Table 1).

Table 1. Socio-demographic and reproductive characteristics of cases and controls.

| Characteristics                        | Total (N=300) No (%) | Cases (N=100) No (%) | Controls (N=200) No (%) | X2   | p-value |
|----------------------------------------|----------------------|----------------------|-------------------------|------|---------|
| Age range (years)                      |                      |                      |                         |      |         |
| 25-38                                  | 125 (41.7)           | 29 (29.0)            | 96 (48.0)               | 21.1 | 0.001   |
| 39-52                                  | 120 (40.0)           | 39 (39.0)            | 81 (40.5)               |      |         |
| 53-65                                  | 55 (18.3)            | 32 (32.0)            | 23 (11.5)               |      |         |
| Marital status                         |                      |                      |                         |      |         |
| Divorced                               | 4 (1.3)              | 2 (2.0)              | 2 (1.0)                 | 5.50 | 0.141   |
| Married                                | 180 (60.0)           | 61 (61.0)            | 119 (59.5)              |      |         |
| Single                                 | 95 (31.7)            | 26 (26.0)            | 69 (34.5)               |      |         |
| Widowed                                | 21 (7.0)             | 11 (11.0)            | 10 (5.0)                |      |         |
| Profession                             |                      |                      |                         | 7.20 | 0.066   |
| Traders                                | 47 (15.7)            | 12 (12.0)            | 35 (17.5)               |      |         |
| Salary jobs                            | 115 (38.3)           | 34 (34.0)            | 81 (40.5)               |      |         |
| Housewives                             | 85 (28.3)            | 38 (38.0)            | 47 (23.5)               |      |         |
| Unemployed                             | 53 (17.7)            | 16 (16.0)            | 37 (18.5)               |      |         |
| Level of education                     |                      |                      |                         | 3.60 | 0.310   |
| Illiterates                            | 7 (2.3)              | 1 (1.0)              | 6 (3.0)                 |      |         |
| Primary                                | 46 (15.3)            | 20 (20.0)            | 26 (13.0)               |      |         |
| Secondary                              | 140 (46.7)           | 46 (46.0)            | 94 (47.0)               |      |         |
| Tertiary                               | 107 (35.7)           | 33 (33.0)            | 74 (37.0)               |      |         |
| Smoking                                |                      |                      |                         | 0.31 | 0.854   |
| Former                                 | 8 (2.7)              | 2 (2.0)              | 6 (3.0)                 |      |         |
| Occasional                             | 10 (3.3)             | 3 (3.0)              | 7 (3.5)                 |      |         |
| Never                                  | 282 (94.0)           | 95 (95.0)            | 187 (93.5)              |      |         |
| Alcohol consumption                    |                      |                      |                         | 6.96 | 0.073   |
| Permanent                              | 19 (6.3)             | 4 (4.0)              | 15 (7.5)                |      |         |
| Occasional                             | 10 (3.3)             | 1 (1.0)              | 9 (4.5)                 |      |         |
| Never                                  | 55 (18.3)            | 14 (14.0)            | 41 (20.5)               |      |         |
| Occasional                             | 216 (72.0)           | 81 (81.0)            | 135 (67.5)              |      |         |
| Use of oral contraception              |                      |                      |                         | 0.77 | 0.858   |
| Former                                 | 4 (1.3)              | 1 (1.0)              | 3 (1.5)                 |      |         |
| Permanent                              | 18 (6.0)             | 7 (7.0)              | 11 (5.5)                |      |         |
| Occasional                             | 78 (26.0)            | 28 (28.0)            | 50 (25.0)               |      |         |
| Never                                  | 200 (66.7)           | 64 (64.0)            | 136 (68.0)              |      |         |
| Use of condom                          |                      |                      |                         | 2.50 | 0.290   |
| Always                                 | 21 (7.0)             | 6 (6.0)              | 15 (7.5)                |      |         |
| Occasional                             | 180 (60.0)           | 55 (55.0)            | 125 (62.5)              |      |         |
| Never                                  | 99 (33.0)            | 39 (39.0)            | 60 (30.0)               |      |         |
| Parity                                 |                      |                      |                         | 3.91 | 0.141   |
| <3                                     | 111 (37.0)           | 30 (30.0)            | 81 (40.5)               |      |         |
| 3-5                                    | 63 (21.0)            | 26 (26.0)            | 37 (18.5)               |      |         |
| >5                                     | 126 (42.0)           | 44 (44.0)            | 82 (41.0)               |      |         |

3.2. Molecular Detection of hr HPV- DNA Types Among Cases and Controls

Of the 300 participants, 213 (71.0%) [95%CI: 65.7-76.0] were hr HPV-DNA positive among whom, 82 (82.0%) were cases compared to 131 (65.5%) controls. HPV infections were statistically different among cases and controls (p=0.003). HPV multiple infections were found in 112 (37.3%) [95%CI: 31.7-43.0] participants among whom 38 (38.0%) were cases and 74 (37.0%) were controls (Table 2).

Table 2. Molecular detection of hr HPV among cases and controls.

| Hr HPV infection | Total No (%) | Cases No (%) | Controls No (%) | OR (95% CI) | p-value |
|------------------|--------------|--------------|-----------------|-------------|---------|
| HPV-DNA          |              |              |                 | 2.40 (1.33-4.31) | 0.004   |
| Positive         | 213 (71.0)   | 82 (82.0)    | 131 (65.5)      |             |         |
| Negative         | 87 (29.0)    | 18 (18.0)    | 69 (34.5)       |             |         |
| Total            | 300 (100)    | 100 (33.3)   | 200 (66.6)      |             |         |
| Multiple infections |          |              |                 | 1.04 (0.64-1.71) | 0.866   |
| Positive         | 112 (37.3)   | 38 (38.0)    | 74 (37.0)       |             |         |
| Negative         | 188 (62.7)   | 62 (62.0)    | 126 (63.0)      |             |         |
| Total            | 300 (100)    | 100 (33.3)   | 200 (66.6)      |             |         |
3.3. Molecular Diversity of High Risk HPV-DNA Types Among Cases and Controls

The overall hr HPV-DNA detection was: 98 (32.7%) for HPV16, 19 (6.3%) for HPV31, 36 (12.0%) for HPV33, 29 (9.7%) for HPV35, 39 (13.0%) for HPV39, 25 (8.3%) for HPV45, 16 (5.3%) for HPV59, 14 (4.7%) for HPV52, 11 (3.7%) for HPV56, 13 (4.3%) for HPV58 and 54 (18.0%) for HPV66 (Table 3). Among cases hr HPV-DNA was detected in 29 (29.0%) for HPV16, 12 (12.0%) for HPV33, 13 (13.0%) for HPV35, 14 (14.0%) for HPV39, 14 (14.0%) for HPV45 and 20 (20.0%) for HPV66. In controls, hr HPV-DNA detection was as followed: 69 (34.5%) for HPV16, 24 (12.0%) for HPV33, 25 (12.5%) for HPV18 and 27 (13.5%) for HPV39. HPV16 was involved in most multiple infections. The most prevalent co-infections were observed in 27 (9.0%) for HPV16/66 and in 22 (7.3%) for HPV16/18 (Table 3).

Table 3. Molecular diversity of hr HPV-DNA types among cases and controls.

| Hr HPV genotypes | Total (N=300) No (%) | Cases (N=100) No (%) | Controls (N=200) No (%) | X² | p-value | aOR 95% CI | p-value |
|------------------|---------------------|---------------------|------------------------|----|--------|------------|--------|
| HPV16            | 98 (32.7)           | 29 (29.0)           | 69 (34.5)              | 0.92 | 0.338 |            |        |
| HPV31            | 19 (6.3)            | 5 (5.0)             | 14 (7.0)               | 0.45 | 0.503 |            |        |
| HPV33            | 36 (12.0)           | 12 (12.0)           | 24 (12.0)              | 0.00 | 1.000 |            |        |
| HPV35            | 29 (9.7)            | 13 (13.0)           | 16 (8.0)               | 1.90 | 0.167 |            |        |
| HPV18            | 39 (13.0)           | 17 (17.0)           | 21 (12.5)              | 0.13 | 0.716 |            |        |
| HPV39            | 44 (14.7)           | 17 (17.0)           | 27 (13.5)              | 0.65 | 0.419 |            |        |
| HPV45            | 25 (8.3)            | 17 (17.0)           | 11 (5.5)               | 6.03 | 0.012 |            |        |
| HPV59            | 16 (5.3)            | 6 (6.0)             | 10 (5.0)               | 0.13 | 0.716 |            |        |
| HPV52            | 14 (4.7)            | 8 (8.0)             | 6 (3.0)                | 3.74 | 0.053 |            |        |
| HPV56            | 11 (3.7)            | 6 (6.0)             | 5 (2.5)                | 3.21 | 0.128 |            |        |
| HPV58            | 13 (4.3)            | 3 (3.0)             | 10 (5.0)               | 0.64 | 0.423 |            |        |
| HPV66            | 54 (18.0)           | 20 (20.0)           | 34 (17.0)              | 0.13 | 0.716 |            |        |
| Multiple hr HPV infections | | | | | |
| HPV16/66 | 27 (9.0) | 3 (11.1) | 24 (88.9) | 7.11 | 0.008 |        |        |
| HPV16/18 | 22 (7.3) | 8 (36.4) | 14 (63.6) | 0.99 | 0.754 |        |        |
| HPV33/39 | 16 (5.5) | 8 (50.0) | 8 (50.0) | 2.11 | 0.146 |        |        |

3.4. Sero-diagnosis of Chlamydia Trachomatis Infections Among Cases and Controls

C. trachomatis antibodies were detected in 30 [10.0%, 95% CI: 6.3-13.3] cases for IgM, 70 [23.3%, 95% CI: 18.3-28.3] cases for IgA and 77 [25.7%, 95% CI: 21.0-30.3] cases for IgG. Among cases, 4 (4.0%), 17 (17.0%) and 22 (22.0%) participants were positive for IgM, IgA and IgG respectively compared to 26 (13.0%), 53 (36.5%) and 55 (27.5%) for controls. IgM participants had higher odds of cervical cancer than those negative (aOR=3.50; 95%CI: 1.16-10.49; p=0.025) (Table 4).

Table 4. Sero-diagnosis of C. trachomatis infections among cases and controls.

| Ab Types | Total No (%) | Cases No (%) | Controls No (%) | OR 95% CI | p-value | aOR 95% CI | p-value |
|----------|--------------|--------------|-----------------|-----------|---------|------------|---------|
| IgM      |              |              |                 |           |         |            |         |
| Positive | 30 (10.0)    | 4 (4.0)      | 26 (13.0)       | 3.60 (1.2-10.6) | 0.014 | 3.50 (1.2-10.5) | 0.025 |
| Negative | 270 (90.0)   | 96 (96.0)    | 174 (87.0)      |           |         |            |         |
| Total    | 300 (100)    | 100 (39.3)   | 200 (66.7)      |           |         |            |         |
| IgA      |              |              |                 |           |         |            |         |
| Positive | 70 (23.3)    | 17 (17.0)    | 53 (26.5)       | 1.80 (0.9-3.3) | 0.067 | 1.60 (0.8-3.0) | 0.156 |
| Negative | 230 (76.7)   | 83 (83.0)    | 147 (73.5)      |           |         |            |         |
| Total    | 300 (100)    | 100 (33.3)   | 200 (66.7)      |           |         |            |         |
| IgG      |              |              |                 |           |         |            |         |
| Positive | 77 (25.7)    | 22 (22.0)    | 55 (27.5)       | 1.35 (0.8-2.4) | 0.304 | 1.12 (0.6-2.0) | 0.720 |
| Negative | 223 (74.3)   | 78 (78.0)    | 145 (72.5)      |           |         |            |         |
| Total    | 300 (100)    | 100 (33.3)   | 200 (66.7)      |           |         |            |         |
| IgG/IgM  |              |              |                 |           |         |            |         |
| Positive | 13 (4.3)     | 1 (1.0)      | 12 (6.0)        | 0.045     | -       |            | -       |
| Negative | 287 (95.7)   | 99 (99.0)    | 188 (84.5)      |           | -       |            | -       |
| Total    | 300 (100)    | 100 (33.3)   | 200 (66.7)      |           | -       |            | -       |

3.5. High Risk HPV-DNA/C. trachomatis Co-infections Among Cases and Controls

Hr HPV-DNA/C. trachomatis IgM was detected in 4 (4.0%) cases compared to 16 (8.0%) controls, hr HPV-DNA/C. trachomatis IgA in 13 (13.0%) cases compared to 36 (18.0%) controls and hr HPV-DNA/C. trachomatis IgG in 20 (20.0%) cases compared to 33 (16.5%) controls (Table 5).
4. Discussion

4.1. Characteristics of Cases and Controls

Participants in this study were aged between 25- 65 (mean=41.1 +/- 10.5) years quite different from that of another study which included participants aged between 35 - 78 (mean=53.2 +/-9.8 years) [19]. The mean ages of our cases (mean=44.7 years) and controls (mean=39.3 years) were lower than that reported in India (cases mean=50.6 years and controls mean=45.5 years) [20] but greater than 36.89 years recorded in women with cervical cancer in the Northern Region of Cameroon [21]. The characteristics of cases and controls were similar except for their age. A case-control study in Egypt reported no significant differences between patient and control groups as regarding risk factors of cervical cancer as age, educational level, parity, sexarche, total life time sex partner, smoking and contraceptive history [22].

4.2. Prevalence of hr HPV Among Cases and Controls

The overall prevalence of hr HPV genotypes was 71.0% for single and 37.3% for multiple types, similar to 71.9% in Angola [23] but higher than 35.9% and 41.4% for multiple hr HPV types in USA [24]. Compared to Cameroon, a well implemented HPV vaccine programme might have contributed to a reduced risk of HPV infection in the USA. We found high prevalence of hr HPV infections among cases compared to controls which was similar to the findings of another study in Brazil [2016] which reported high prevalence of HPV in women with LSIL than in women with negative cytology [25]. The disparities observed in the prevalence of HPV infections between studies may be justified by the epidemiologic diversity of the virus types, factors favouring the persistence or clearance of the virus, the diagnostic range of the HPV kits and the selection criteria of the study population. Findings of high prevalence of hr HPV-DNA types in the current study might be due to the persistence of the infection while lower prevalence in controls might presumably be attributed to the immunological clearance of the virus [26].

HPV 16 and HPV 18 were identified in most studies as the most prevalent oncogenic HPV types worldwide [16, 23, 24, 27]. Our results showed HPV 16 as the most prevalent hr HPV type followed in decreasing order of frequency by HPV 66, HPV 39, HPV18 and HPV 33 which was different from another study in Cameroon which reported HPV16 and HPV18 to account for 36.3% of HPV infection [28]. In another part of Africa, HPV 52 followed by HPV 35, HPV 16, HPV 53, HPV58, HPV 6 and HPV 51 were most prevalent in Mozambique thus, showing some difference with our findings presumably resulting from the range of HPV genotyped [29]. Still in this study, HPV 39 and HPV 45 were most frequent in cases compared to controls. Findings of HPV 39 (17%) in high prevalence than that of a worldwide (3%) report further supported its role in cervical cancer as suggested by Wohlmeister et al. (2016) [25]. Our results suggest HPV 39, HPV 45 and HPV 66 as the emerging oncogenic HPV genotypes associated to increased cervical cancer incidence in Cameroon; as such we suggest their consideration during epidemiological studies and future vaccine development as effective preventive measures. Unfortunately, facilities for HPV genotyping and effective HPV vaccination programme are lacking in Cameroon [16].

The most prevalent multiple-infections observed in our population were HPV 16/66, HPV 16/18, and HPV 33/39 with HPV 16/18 and HPV 33/39 being associated with the risk of progression to precancerous lesions. There are disparities in the distribution of HPV multiple-infections according to studies with HPV 66/53, HPV 16/53 and HPV 16/58), HPV 6/35, HPV 6/66 [23] being reported in Angola and HPV 31/35 in Nigeria [2017] [30].

4.3. Prevalence of C. trachomatis Among Cases and Controls

*C. trachomatis* is one of the most prevalent sexually transmitted pathogens in the world. Most urogenital *C. trachomatis* infections are initially asymptomatic and may subsequently cause considerable long-term morbidity. In
most cases, *C. trachomatis* antibodies may be the only indication of active/past *C. trachomatis* involvement [31].

The prevalence of *C. trachomatis* varies greatly in different studies. The global prevalence for *C. trachomatis* infection was estimated to 3.8% [32]. Higher prevalence such as 26% was found in Nigeria, [33] and 26.4% in Argentina [34]. Our results showed the overall sero-prevalence of *C. trachomatis* antibodies in decreasing order to be 25.7% for IgG, 23.3% for IgA and 10.0% for IgM. In Rwanda, the IgG prevalence of *C. trachomatis* antibodies was 18.8% in sub-fertile and 18.3% fertile and IgA prevalence rates of 7.4% in sub-fertile and 4.1% in the fertile women lower than in our report [31]. The disproportionate burden of *C. trachomatis* infection in most studies might be attributed to unsafe socio-behavioral characteristics of the study population in addition to the choice of the diagnostic technique with the sero-diagnosis yielding higher prevalence due to cross-reactivity than the molecular technique which more accurate [33, 35].

### 4.4. *C. trachomatis* as an Independent Predictor of Cervical Cancer

We investigated and found high prevalence of *C. trachomatis* in controls than in cases which were in disagreement with Adegbesan-Omilabu *et al.* (2014) in Nigeria who reported higher prevalence of *C. trachomatis* infection in cases than in controls [36]. Equally, Kwaśniewska *et al.* (2007) reported a significantly higher frequency of *C. trachomatis* occurrence in tissue sections from patients with invasive cervical cancer compared to control without neoplastic lesions [37].

*C. trachomatis* infection as predictor of cervical cancer has also been subject of controversies. There are suggestions that *C. trachomatis* independently initiate cervical carcinogenesis through cellular transformation and tumour development thus suggesting that its detection in serum might be a possible method to predict the risk of cervical cancer in clinic [12]. In the contrary, another author reported that *C. trachomatis* was not significantly associated with cervical cancer in prevalent cases [38]. By sero-diagnosis we found that, *C. trachomatis* (IgA, IgG) was not significantly associated with the increased risk of cervical cancer among cases compared to controls. In the contrary, *C. trachomatis* IgM a marker of primo-infection was significantly associated with cervical cancer but its implementation as predictor of cervical cancer might not be practically feasible considering its short half-life time in the circulation. As such, the role of *C. trachomatis* as independent predictor of cervical cancer can accurately be evaluated using cell culture which requires further investigations.

### 4.5. *C. trachomatis* as Co-factor for Hr HPV Infection in Developing Cervical Cancer

There are suggestions that co-infections with HPV/*C. trachomatis*, HPV/gonorrhoea followed by HPV/syphilis and HPV/HIV [37] may increase a woman’s risk of developing cervical neoplasia [11] since cellular damage caused by *C. trachomatis* infection promotes HPV acquisition or persistence. Such observations were supported by the findings of a significantly higher prevalence of *C. trachomatis* infection in women with positive HPV- DNA than controls as well as in infections with one or multiple viral types [34].

From our results, the overall prevalence of *C. trachomatis*/HPV co-infections was 17.7%, 16.3% and 6.7% for IgG, IgA and IgM respectively which was higher than 8.6% found in Uganda (2019) [39] and 5.6% in Iran (2018) [40]. The prevalence of HPV/*C. trachomatis* co-infections is low in most studies when assessed by DNA using PCR technique than by antibodies testing presumably because of the high specificity of DNA testing. The association of HPV/*C. trachomatis* and its role in developing cervical cancer remains a matter of debates. Some authors suggested that reactivation or persistence of HPV following the co-infection with *C. trachomatis* might support such association [13]. There are two suggestions supporting the association of HPV/*C. trachomatis* in developing cervical cancer. The first hypothesis was that *C. trachomatis* acts as a co-factor trough immune system modulation to favour HPV acquisition/persistence [41]. The second hypothesis being that, the association between these two agents is more related to a mutual potentiation than to the fact that they share a common route of transmission [34]. Adding to the findings of high prevalence of HPV in *C. trachomatis* infected women [42], another author in Egypt documented high prevalence of HPV/*C. trachomatis* co-infections in HPV-infected cancer patients than in HPV- infected control cases [22]. In the current study, the prevalence of *C. trachomatis*/HPV co-infection was not significantly high in cases than in controls for IgG presumably as the result of persisting IgG of past infection. These findings were in line with a similar case-control study where Smelove *et al.* (2016) found *C. trachomatis* not associated with increased risks of subsequent invasive adenocarcinoma and adenosquamous in situ [42]. Another study in Greece (2018) also reported that *C. trachomatis* detection was associated with the presence of hr-HPV and mixed hr- and hr-HPV but not with hr HPV alone [7].

Despite high prevalence of *C. trachomatis* IgG in cases than in controls which may be attributed to past infection, our data showed no significant association between *C. trachomatis* (IgG/IgM/IgA)/HPV co-infection and cervical cancer thus suggesting that *C. trachomatis* might not be a co-factor of hr HPV in initiating cervical cancer.

### 5. Conclusion

Cervical cancer is a chronic disease of women with high morbidity and mortality in Cameroon. Our study suggested a high prevalence hr HPV- DNA among cases than controls. HPV 16 and HPV 66 were the most frequent genotypes found among cases and controls. *C. trachomatis* antibodies were prevalent among cases and controls with the controls bearing the highest burden of the infection. Serologically, *C. trachomatis* infection was not significantly associated with
the risk of precancerous lesions among Cameroonian women. Assessment of the hr HPV-DNA/C. trachomatis co-infections revealed high prevalence of the co-infections among controls than cases but with no statistical significance in this study. From our data, we came to the conclusion that C. trachomatis infection assessed by serology was neither a predictor nor a co-factor for hr HPV in causing cervical cancer among Cameroonian women. However, further studies become necessary to establish their mutual actions in the development of cervical cancer using accurate diagnostic techniques like Chlamydia cell culture and PCR. Meanwhile, co-morbidity of C. trachomatis and hr HPV can be prevented by a sustainable national information/education programme on safe sex behaviour and practice.

Authors’ Contributions

WB: The main investigator contributed in study design, sample collection, data management and statistical analysis and drafted the manuscript. DSN: Contributed in study design, suggested appropriate statistical analysis and revised the manuscript. ANJC: Contributed in study design and revision of the manuscript. TNN: Provided the logistic for patient recruitment, contributed in sample collection and revised the manuscript.

All authors read and approved the final manuscript.

Conflict of Interest

The authors declare that they have no competing interests.

Acknowledgements

We are very grateful to Vircell Microbiologists, Vircell, S. L. Parque Tecnologico de la Salud, Avicena 8, 18016 Granada, Spain. Tel. + 34 958 441 264 for assisting us with the chlamydia kits used for this study. We sincerely thank the administration of the respective hospitals, women who participated in this study and healthcare personnel for their sincere collaboration. We also thank Dr Pokam Thumamo David Benjamin for reviewing this manuscript.

References

[1] Manga MM, Fowotade A, Abdullahi YM, El-nafaty AU, Adamu DB, Pindiga HU, Bakare RA and Osoba AO. Epidemiological patterns of cervical human papillomavirus infection among women presenting for cervical cancer screening in North-Eastern Nigeria. Infect Agents Cancer. 2 October 2015; 10: 39.

[2] Owki LA, Othiene E, Wandabwa J, Okoth A. Prevalence of cancerous and pre-malignant lesions of cervical cancer and their association with risk factors as seen among women in the regions of Uganda. J Clinic Laboratory Med. 8 March 2017; 2.1.

[3] Bouassa R-S M, Prazuck T; Lethu T, Jenabian M-A, Meye J-F; Bélec L. Cervical cancer in sub-Saharan Africa: a preventable noncommunicable disease. Expert Review of Anti-infective Therapy. 5 May 2017; 15 (6): 613-627.

[4] Ghittoni R, Accardi R, Chiocca S and Tommasino M. Role of human papilloma viruses in carcinogenesis. ecaner. 29 April 2015; 9: 526.

[5] Clarke MA, Rodriguez AC, Gage JC, Herrero R, Hildesheim A, Wacholder S, Schiffman RBM. A large, population-based study of age-related associations between vaginal pH and human papillomavirus infection. BMC Infect Dis. 8 February 2012, 12: 33.

[6] Bhatla N, Puri K, Joseph E, Kriplani A, Iyer VK & Sreenivas V. Association of Chlamydia trachomatis infection with human papillomavirus (HPV) & cervical intraepithelial neoplasia - A pilot study. Indian J Med Res. March 2013; 137: 533-539.

[7] Parthenisa C, Panagopoulosa P, Margarib N, Kottaridib C, Spathis A, Pouliakisis A, Konstantoudakis S, Chrelisa G, Chrelisa C, Papatontomia N, Ioannis G. Panayiotides, Tsiodras S. The association between sexually transmitted infections, human papilloma virus, and cervical cytology abnormalities among women in Greece. Intern J Infect Dis. 5 June 2018; 73: 72–77.

[8] Malhotra M, Sood S, Mukherjee A, Muralidhar S & Bala M. Genital Chlamydia trachomatis: An update. Indian J Med Res. October 2013; 138: 33-316.

[9] Richard PM. New insights into a persistent problem: Chlamydia infections. J. Clin. Invest. 1 June 2003; 111: 1647–1649.

[10] Bekolo CE, O’Bryan G, Tchago FE, Nangue C, Bekoule PS, Kollo B. Integrating cervical cancer screening with HIV care in Cameroon: Comparative Risk Analysis of Cervical Disease in HIV-infected women receiving antiretroviral therapy to women in the general Population. PLoS ONE. 11 February 2016, 11 (2): e0149152.

[11] De Castro-Sobrinho JM, Rabelo-Santos SH, Alves RRF, Derchain S, Sarian LOZ, Pitta DR, Campos EA and Zeferino LC. Chlamydia trachomatis Co-infection in HPV Positive Women brings no Additional Risk of High-grade Cervical Intraepithelial Neoplasia. J Cytol Histol. November 20, 2015, S3: 2.

[12] Zhu H, Shen Z, Luo H, Zhang W, and Zhu X. Chlamydia Trachomatis Infection- Associated Risk of Cervical Cancer. A Meta-Analysis. Medicine. Marsh 2016: 95 (13): e377).

[13] Samoff E, Koumans EH, Markowitz LE, Sternberg M, Sawyer MK, Swan D, Papp JR, Black CM, and Unger ER. Association of Chlamydia trachomatis with Persistence of High-Risk Types of Human Papillomavirus in a Cohort of Female Adolescents. Am J Epidemiol. January 13, 2005; 162: pp 668-675.

[14] Tungsrithorn N, Kasinpila C, Manecinin C, Namujju PB, Lehtinen M, Anttila A, Promthet S. Lack of Significant Effects of Chlamydia trachomatis Infection on Cervical Cancer Risk in a Nested Case-Control Study in North-East Thailand. Asian Pacific J Cancer Prev. 15 July 2014; 15 (3): 1497-1500.

[15] Charan J and Biswas T. How to Calculate Sample Size for Different Study Designs in Medical Research? Indian J Psychol Med. April-June 2013; 35 (2): 121–126.
[16] Doh G, Ikomey MG, Njenda D, Gichana J, Katusiime MG, Ndze VN, Zeier M, Mesembe M, Fukkan G, Assoumou OCM, Tebeu PM, Atangana PA, Jacobs GB. Oncogenic Human Papillomavirus Genotypes 16 and 18 Prevalence Among Women with Normal Cervical Cytology and Neoplasia in Cameroon: A Systematic Review. Health Sci. Dis. August-September 2017; 18 (3).

[17] Debrah O, Agyemang-Yeboah F, Asmah RH, Timmy-Donkoh E, Seni MM, Koudjo LA, Nkol Sight and Owusu-Dabo E. Sero-prevalence of herpes simplex virus type 1 and type 2 among women attending routine Cervicare clinics in Ghana. BMC Infect. Dis. 7 August 2018; 18: 378.

[18] Sankaranarayanan R, Wesley RS. A Practical Manual on Visual Screening for Cervical Neoplasia IARC Technical Publication No. 41 IARC Press, 2003.

[19] Sharma P, Pattanashetty SM. A study on risk factors of cervical cancer among patients attending a tertiary care hospital: A case-control study. Clinic Epidemiol Global Health 6 3 October 2017; 2018; 83-87.

[20] Mohann P, Shetty S. A Case Control Study on the Risk Factors of Cervical Cancer among Women in a Coastal City of South India. Intern J Sci Research (IJSR). July 2015; 4 (7): 2049-2051.

[21] Kalgong G, Kamdj NHA, Tagne SR, Nangue C. Sensitivity and specificity of visual inspection with acetic acid (VIA) and with Lugol Iodine (VILI) in the diagnosis of cervical cancer in the Northern Region of Cameroon. Int. Biol. Biomed. J. 25 Marsh 2017; 3 (2).

[22] Girgis SA, kassem NN and Eltohamy OA. Chlamydia trachomatis and Human Papilloma Virus (HPV) infection in Egyptian Patients with Invasive Cancer Cervix- A Case Control Study. Int. J. Curr. Microbiol. App. Sci. Volume 4 Number 6 (2015) pp. 937-949.

[23] Damião PDA, Oliveira-Silva M, Moreira MA, Poliakova N, De Lima MERT, Chiyou J, Nicol AF, & Human Papillomavirus types distribution among women with cervical preneoplastic, lesions and cancer in Luanda, Angola. Pan Afr Med J. 22 July 2016; 24: 268.

[24] Winer RL, Hughes JP, Feng Q, Xi LF, Lee SK, O'Reilly SJ, Kivist N, and Koutsyka LA. Prevalence and risk factors for oncogenic HPV infections in high-risk mid-adult women. Sex Transm Dis. November 2012; 39 (11): 848-856.

[25] Wohlmeister D, Vianna DRB, Helfer VE, Gimenes F, Consolaro MEL, Barcelos RB, Rossetti ML, Calil LN, Buffon A, Pilger DA. Association of human papillomavirus and Chlamydia trachomatis with intraepithelial alterations in cervix samples. Mem Inst Oswaldo Cruz, Rio de Janeiro. February 2016; 111 (2): 106-113.

[26] Nathphopsuk S, Sethheetam-Ishida W, Sinawat S, Pientong C, Yuenyao P, Shida T. Risk factors for cervical cancer in Northern eastern Thailand: detailed analyses of sexual and smoking behaviour. Asian Pacific J cancer. November 2012; 13 (11): 5499-5495.

[27] Okechukwu A. Ibeanu. Molecular pathogenesis of cervical cancer. Cancer Biol Therapy. 1 February 2011. 11 (3): 295-306.

[28] Pirek D, Petignat P, Vasilakos P, Gourmaud J, Pache JC, Rubbia-Brandt L, Zacharie Sand Z, Mckee, Liza Ho TA. Human papillomavirus genotype distribution among Cameroon women with invasive cervical cancer: a retrospective study. Sex Transm Infect. 6 Marsh 2015; 91: 440-444.

[29] Omar VE, Orvalho A, Nàlia I, Malin K, Gabriella LL, Torbjörn R, Charlotta N, Kerstin F, Nafissa O, Vindorai JI, Sören A. Human papillomavirus prevalence and genotype distribution among young women and men in Maputo city, Mozambique. BMJ Open 17 July 2017; 7: e015653.

[30] Okunade KS, Nwogu CM, Oluwole AA. Anorlu RI. Prevalence and risk factors for genital high-risk human papillomavirus infection among women attending the outpatient clinics of a university teaching hospital in Lagos, Nigeria. Pan Afr Med J. 14 November 2017; 28: 227.

[31] Muvunyi CM, Dhont N, Verhelst R, Temmerman M, Cleyers G, and Padalko E. Chlamydia trachomatis infection in fertile and subfertile women in Rwanda: prevalence and diagnostic significance of IgG and IgA antibodies testing. Human Reprod. 20 October 2011; 26, (12): 3319-3326.

[32] Rowley J, Hoorn SV, Korenromp E, Low N, Unne M, Abur-Raddad LJ, Chico RM, Smolak A, Newman L, Gottlieb S, Thwin SS, Broutet N & Taylora MM. Chlamydia, gonorrhea, trichomoniasis and syphilis: global prevalence and incidence estimates, 2016. Bull World Health Organ. 1 August 2019; 97: 548-562.

[33] Ige OT, Ige SO, Olayinka AT. Prevalence of Chlamydia Trachomatis infection among women of reproductive age group in a tertiary hospital in Northern Nigeria. Ann Trop Pathol. 24 October 2018; 9: 17-21.

[34] Dehua GD, Schelover JBE, Vasquez ND, Alonso JM, Marin HM, Lucero RH, Picconi MA. Chlamydia trachomatis as a probable cofactor in human papillomavirus infection in aboriginal women from northeastern Argentina. Braz J Infect Dis. November-December 2011; 15 (6): 567-572.

[35] Pinto VM, Tancredi MV, De Carvalho da Silva RJ, Khoury Z and Buchalla CM. Prevalence and factors associated with Chlamydia trachomatis infection among women with HIV in São Paulo. Rev Soc Bras Med Trop. May-June 2016; 49 (3): 312-318.

[36] Adegbesan-Omilabu MA, Okunde KS, Oluwole AA, Gbadegesin A, Omidlabu SA. Chlamydia trachomatis among women with normal and abnormal cervical smears in Lagos, Nigeria. Int J Reprod Contracept Obstet Gynecol. 21 August 2014; 3 (3): 501-506.

[37] Kwaśniewska A, Skoczyski M, Korobowicz E, Semezuk M, and Goździcka-Józefiak A. Prevalence of chlamydia trachomatis in cervical and vulvar carcinoma of the Lublin region patients. Bull Vet Inst Pulawy. 18 July 2007; 51: 357-360.

[38] Naucler J, Persson K, You S-L, Hsieh C-Y, Sun N-A, Sören A. Chlamydia trachomatis infection among women with normal and abnormal cervical smear in Lagos, Nigeria. Int J Reprod Contracept Obstet Gynecol. 21 August 2014; 3 (3): 501-506.

[39] Ssedyabane F, Amnia DA, Mayanja R, Omonigho A, Ssauna C, Najjuma JN, and Freddie B. HPV-Chlamydial Co-infection, Prevalence, and Association with Cervical Intraepithelial Lesions: A Pilot Study at Mbarara Regional Referral Hospital. J Cancer Epidemiol. 10 January 2019: (7).
[40] Javanmard D, Behravan M, Ghannadkafi M, Salehabadi A, Ziaee M, Namaei MH. Detection of Chlamydia trachomatis in Pap Smear Samples from South Khorasan Province of Iran. Int J Fertil Steril. 15 January 2018; 12 (1): 31-36.

[41] Silins I, Ryd W, Strand A, Tommberg S, Hansson BG, Wang X, Arnheim L, Dahl V, Bremell D, Persson K, Dillner J and Rylander E. Chlamydia trachomatis infection and persistence of human papillomavirus. Int. J. Cancer. 8 March 2005; 116: 110-115.

[42] Smelov V, Gheit T, Sundström K, Ploner A, McKay-Chopin S, Eklund C, Tommasino M, Dillner J. Lack of Significant Effects of Chlamydia trachomatis Infection on Cervical Adenocarcinoma Risk: Nested Case-Control Study. PLoS ONE. May 26, 2016; 11 (5): e0156215.